biostudies-literatureUnknown13(7)Tanaka YGilead Sciences K.K.<h4>Introduction</h4>Although patients with HBV have a risk of reactivation after immunosuppressive therapy (IST), the status of their risk management is unclear in Japan. This study aims to describe the proportion of patients who received preventive management of HBV reactivation during ISTs in patients with chronic HBV infection of HBsAg or resolved HBV infection.<h4>Method</h4>A retrospective cohort study was conducted using the JMDC Japanese claims database from April 2011 to June 2021. Patients with HBV infections of HbsAg who received ISTs or patients who had resolved HBV infections who received ISTs were identified from the database and evaluated for appropriate management to prevent HBV reactivation.<h4>Results</h4>In total, 6242 eligible patients were identified. The proportions oInfectious diseases and therapy1607-1620https://www.ebi.ac.uk/biostudies/studies/S-EPMC11219601biostudies-literatureImplementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy.PMC11219601Nakamoto DTanaka YKwon KMSaito YDickinson HPiao YMizutani HWakabayashi RfalseImplementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy.<h4>Introduction</h4>Although patients with HBV have a risk of reactivation after immunosuppressive therapy (IST), the status of their risk management is unclear in Japan. This study aims to describe the proportion of patients who received preventive management of HBV reactivation during ISTs in patients with chronic HBV infection of HBsAg or resolved HBV infection.<h4>Method</h4>A retrospective cohort study was conducted using the JMDC Japanese claims database from April 2011 to June 2021. Patients with HBV infections of HbsAg who received ISTs or patients who had resolved HBV infections who received ISTs were identified from the database and evaluated for appropriate management to prevent HBV reactivation.<h4>Results</h4>In total, 6242 eligible patients were identified. The proportions o2024-01-01T00:00:00Z2024 Jul2025-04-04T23:54:32.993Z2025-04-04T23:54:32.993ZS-EPMC112196013880936710.1007/s40121-024-00997-0